title: Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study.
abstract: Accumulating evidence has suggested that the human leucocyte antigen-G (HLA-G) 14 bp ins/del polymorphism might be related to cancer susceptibility. However, epidemiologic findings have been inconsistent. Therefore, we performed a meta-analysis of case-control study to derive a more precise estimation of this association. Electronic databases were searched to identify all eligible studies of HLA-G 14 bp ins/del polymorphism and cancer risk. Odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated to evaluate the strength of the association in fixed-effects model or random-effects model according to heterogeneity. Publication bias, sensitivity analysis and subgroup analyses based on cancer type, ethnicity, source of controls and sample size were also performed. A total of 14 case-control studies, involving 2,757 cases and 3,972 controls, were included in the present meta-analysis. The pooled analysis showed that there is no significant relationship between the HLA-G 14 bp ins/del polymorphism and cancer susceptibility under the genetic models (for the allele model del vs. ins: OR 1.13, 95 % CI 1.00-1.27; for the homozygote comparison model del/del vs. ins/ins: OR 1.22, 95 % CI 0.95-1.56; for the dominant model del/del + ins/del vs. ins/ins: OR 1.15, 95 % CI 0.94-1.42; for recessive model del/del vs. ins/del + ins/ins: OR 1.13, 95 % CI 0.96-1.34; respectively). Subgroup analyses indicated significant association among breast cancer, population based control and the large sample size group in some genetic models. Our investigations demonstrate that genotypes for the HLA-G 14 bp ins/del polymorphism may be not associated with overall cancer risk. In a subgroup meta-analysis, however, HLA-G 14-bp ins/del polymorphism might contribute to breast cancer susceptibility.
authors.affiliation: Department of Chemotherapy, People's Hospital of Gaozhou, No. 89 Xiguan Road, Gaozhou, 525200, Guangdong, China, Taoli121@126.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Haohai
authors.initials: H
authors.lastname: Huang
authors.forename: Dan
authors.initials: D
authors.lastname: Liao
authors.forename: Huahuang
authors.initials: H
authors.lastname: Ling
authors.forename: Bingguang
authors.initials: B
authors.lastname: Su
authors.forename: Maode
authors.initials: M
authors.lastname: Cai
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000235:genetics; D002291:Carcinoma, Papillary / Q000235:genetics; D016022:Case-Control Studies; D004938:Esophageal Neoplasms / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D059951:HLA-G Antigens / Q000235:genetics*; D006801:Humans; D054643:INDEL Mutation; D008113:Liver Neoplasms / Q000235:genetics; D009369:Neoplasms / Q000235:genetics*; D009447:Neuroblastoma / Q000235:genetics; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000235:genetics
chemical_list: D020413:3' Untranslated Regions; D059951:HLA-G Antigens